Is Your IP Ready? Navigating IP Challenges for Commercial-Stage Technologies in Due Diligence and M&A
Presenting as part of an LSI ’26 panel, Knobbe Martens partners Kregg Koch and Sabing Lee joined fellow panelists to explore the complexities of intellectual property management for commercial-stage technologies in the medtech industry, and the...
IP Considerations Following FDA Announcement on Flexibility for Cell and Gene Therapies
Key Takeaways: Manufacturing processes of cell and gene therapies (CGTs) may remain fluid well into development and even after FDA approval, and therefore sponsors of CGTs may benefit from patent...
Knobbe Martens Receives Firm of the Year, Litigation Honors at 2026 Managing IP Americas Awards
IRVINE, Calif., April 10, 2026 – Knobbe Martens is proud to announce that the firm received multiple recognitions at the 2026 Managing IP Awards, including “IP Boutique Firm of the...